Financial Performance - GAAP Net Revenues for Q4 2025 increased by 3.7% to $843 million[4] - GAAP Net Income for Q4 2025 rose by 107% to $29 million[4] - Fiscal Year 2025 GAAP Net Revenues increased by 8.1% to $3.44 billion[5] - Fiscal Year 2025 GAAP Net Income increased by 72% to $125 million[5] - Net revenues for the three months ended January 31, 2026, were $842,623,000, representing a 3.0% increase from $812,406,000 in the same period of 2025[19] - Net income for the year ended January 31, 2026, was $124,787,000, a significant increase from $72,412,000 in 2025, resulting in a net income margin of 3.6%[19] - Net revenues for the year ended January 31, 2026, reached $3,439,536,000, compared to $3,180,753,000 in the previous year, representing an 8.1% increase[31] - Net income for Q4 2025 was $28,775 thousand, representing a significant increase of 106.3% compared to $13,917 thousand in Q4 2024[39] Cash Flow and Assets - Free Cash Flow for Q4 2025 was $55 million, and for Fiscal Year 2025 it was $252 million[4][5] - Cash and cash equivalents increased to $41,191,000 as of January 31, 2026, compared to $30,413,000 at the end of the previous year[21] - Total assets grew to $4,835,710,000 as of January 31, 2026, up from $4,554,689,000 in 2025[21] - Free cash flow for the year ended January 31, 2026, was $252,398,000, compared to a negative free cash flow of $(213,693,000) in 2025[23] Profitability Metrics - Gross profit for the year ended January 31, 2026, was $1,515,757,000, which is 44.1% of net revenues, compared to $1,414,932,000 or 44.5% in 2025[19] - Adjusted gross margin for the year ended January 31, 2026, was 44.2%, slightly down from 44.5% in the previous year[31] - The company reported a gross margin of 44.1% for the year ended January 31, 2026, compared to 44.5% in the previous year[31] - The operating margin for Q4 2025 improved to 11.5%, up from 8.7% in Q4 2024[37] - The EBITDA margin for Q4 2025 was 16.2%, compared to 12.2% in Q4 2024[39] Debt and Liabilities - Total debt as of January 31, 2026, is $2,419,065,000[44] - Total net debt is $2,377,874,000, resulting in a ratio of total net debt to adjusted EBITDA of 4.0[44][46] - The company incurred interest expenses of $225,378,000 for the year ended January 31, 2026, which is 6.5% of total revenues, compared to $230,601,000 or 7.2% in 2025[19] - The interest rate for Term loan B is 6.29% and for Term loan B-2 is 7.02%[44] - The asset-based credit facility has an interest rate of 5.30%[44] Future Projections - Fiscal Year 2026 revenue growth is projected to be between 4% to 8%[7] - Adjusted EBITDA Margin for Fiscal Year 2026 is expected to be between 14% to 16%[7] - First Quarter 2026 revenue growth is projected to decline by 2% to 4%[8] Operational Highlights - RH's 2-year revenue growth outpaced industry peers by 7 to 30 basis points, with RH at 15%[11] - The company plans to open Design Galleries in every major market, targeting revenues of $5 to $6 billion in North America[15] - Selling, general and administrative expenses for Q4 2025 were $264,878 thousand, a decrease of 9.4% from $292,468 thousand in Q4 2024[35] - Adjusted EBITDA for Q4 2025 was $149,141 thousand, an increase of 7.6% from $138,815 thousand in Q4 2024[39]

Financial Results Announcement - AgEagle Aerial Systems, Inc. announced its financial results for the quarter and full year ended December 31, 2025[3]. - The press release detailing the financial results was issued on March 31, 2026[3]. Company Information - The company is listed on the NYSE American under the trading symbol UAVS[2]. - The company has not indicated whether it is an emerging growth company in the filing[2]. Filing and Reporting Details - The report does not include specific financial metrics or performance indicators in the provided content[4]. - The filing is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934[4]. - The report includes a cover page interactive data file as part of the exhibits[6]. - The Chief Financial Officer, Alison Burgett, signed the report on behalf of the company[9]. - The financial statements and exhibits are furnished but not detailed in the current report[5]. Content Limitations - No specific user data, future outlook, or new product developments were mentioned in the provided content[4].

Financial Results - Edible Garden AG Incorporated reported preliminary financial results for the Christmas holiday period on January 6, 2026[4]. - The press release detailing financial results is included as Exhibit 99.1 in the current report[4]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[3].

Technology and Innovation - The company focuses on innovative technology in industrial manufacturing solutions, particularly in additive manufacturing (AM) and surface mount technology (SMT) for electronics and precision applications[33]. - The company has integrated various technologies, including hardware, software, and materials science, to enhance manufacturing capabilities[30]. - The company believes advancements in SMT represent a significant opportunity for growth in high-mix, high-speed electronic assembly[33]. - The company is positioned to capitalize on the increasing demand for additive manufacturing solutions across various industries, including aerospace, automotive, and medical[78]. Mergers and Acquisitions - The company has undergone significant mergers and acquisitions, including the acquisition of Desktop Metal for approximately $179.3 million and Markforged for about $115 million[56][59]. - The company has made non-binding offers to acquire Stratasys but did not complete the special tender offers due to unmet conditions[45]. - Recent acquisitions of Desktop and Markforged have resulted in substantial operating losses, complicating the integration process and potentially affecting future profitability[164]. Financial Performance - The company reported net losses of $293.4 million, $99.9 million, and $57.1 million for the years ended December 31, 2025, 2024, and 2023, respectively, indicating a trend of ongoing financial challenges[161]. - The company anticipates fluctuations in operating results and financial condition due to various uncontrollable factors, affecting market expectations[135]. - The company expects to decrease its research and development expenses in the foreseeable future due to a smaller and more focused organization following recent acquisitions[101]. Strategic Direction - The company aims to transition to a U.S. domestic issuer status as of January 1, 2026, following the effects of its 2025 acquisitions[63]. - The company emphasizes the importance of preserving capital for strategic moves and avoiding a short-term survival mindset[36]. - The company is exploring a comprehensive range of strategic alternatives to maximize shareholder value while reviewing product lines for alignment with long-term objectives[124]. - The company initiated a strategic shift away from acquisitions towards improving its core business, which may face challenges in execution[124]. Compliance and Regulatory Risks - The company is subject to stringent compliance requirements under Interim National Security Agreements with the U.S. Government, which may impose operational constraints[132]. - The company is subject to environmental laws related to the import and export of products, which could lead to compliance costs and potential liabilities[155]. - The Israeli Companies Law may impede mergers or acquisitions, potentially preventing a change of control even under favorable terms[210]. Market and Economic Conditions - The U.S. trade tariffs could increase costs for importing products, potentially reducing profit margins and affecting competitive positioning[129]. - Geopolitical developments and global supply chain disruptions contribute to economic uncertainty, impacting the company's ability to secure financing[217]. - Ongoing military activity and political instability in Israel may adversely affect the company's operations and product development[203]. - Inflation has materially increased in the U.S. and global markets, raising costs for commodities, labor, and materials, which could adversely impact financial condition[217]. Operational Risks - The company faces competition from established manufacturers with greater resources, which may hinder its ability to maintain a competitive position[138]. - Disruptions at major production facilities or third-party service providers could materially damage the company's ability to supply products in a timely manner, adversely affecting revenue[146]. - The reliance on a limited number of suppliers for key components poses risks, including potential production delays and increased costs if suppliers become unavailable[143]. - Changes in management may disrupt operations and affect employee morale, potentially impacting the company's strategic objectives[156]. Intellectual Property and Legal Risks - The company holds approximately 383 patents issued, pending, and allowed worldwide, but uncertainties remain regarding the enforceability and potential challenges of these patents[178]. - The company may incur significant additional legal, accounting, and other expenses as a public entity, which could hinder its ability to achieve profitability[162]. - The company may face significant costs and resource diversion due to potential third-party claims of intellectual property infringement, which could impact product development and commercialization efforts[182]. - The company is involved in multiple lawsuits, including one from Murchinson Ltd., which could divert management attention and result in substantial costs if adverse outcomes occur[172]. Shareholder Considerations - The company does not anticipate paying dividends, which may affect shareholder returns[119]. - ADS holders may not receive the same distributions or dividends as holders of Ordinary Shares, which could lead to a material decline in the value of the ADSs[195]. - The company does not anticipate paying any cash dividends in the foreseeable future, with profits expected to be reinvested in the business[188]. - Raising additional capital through equity or convertible debt may dilute existing shareholders' ownership interests and affect their rights[220]. Cybersecurity and IT Risks - Cybersecurity is a critical component of the company's risk management strategy, integrated into the Crisis Management Plan[226]. - The board of directors oversees cybersecurity risk management, supported by the Crisis Management Team and the Chief Information Security Officer[227]. - The company has implemented security measures to prevent unauthorized access to its information technology networks and products[223]. - Significant disruptions to information technology systems or data breaches could negatively impact business operations and lead to reputational damage[221]. Financial Management - The company maintains cash at financial institutions, with some balances exceeding federally insured limits, posing a risk of loss if these institutions fail[169]. - The company successfully moved all funds held in Silicon Valley Bank (SVB) to other banks after the FDIC took control of SVB, mitigating material risk to its financial condition[171]. - The maximum obligation related to grants from the Israeli Innovation Authority, contingent upon future sales, was $2.2 million plus interest as of December 31, 2025[213].

Economic and Market Conditions - In 2025, Mexico's apparent steel demand fell by approximately 10% year-over-year due to a downturn in economic activity and U.S. trade actions[36]. - The steel industry faces intense competition, which could lead to declining margins and lower sales for Ternium[45]. - Economic and political instability in Mexico, including high inflation and government intervention, poses risks to Ternium's operations and financial condition[124]. - In Argentina, consumer price inflation reached 211% in 2023, 118% in 2024, and 32% in 2025, significantly impacting Ternium's costs and financial position[139]. - The Brazilian economy has faced significant challenges, including inflation and political instability, which could adversely affect Ternium's business results and financial condition[150]. Trade and Regulatory Environment - The U.S. imposed a 25% tariff on steel imports in 2025, which could negatively impact demand for Ternium's products in Mexico[127]. - The unpredictability of U.S. trade measures is affecting market dynamics and could lead to a prolonged trade conflict, impacting Ternium's operations[131]. - Ternium's steel shipments in the U.S. have been adversely affected by U.S. tariffs on Mexican exports, leading to a 10% year-over-year decrease in Mexico's apparent steel demand in 2025[133]. - International trade actions and regulations pose risks to Ternium's sales and revenues, as increased duties on steel imports could raise production costs[162]. - The uncertainty surrounding trade agreements between the U.S. and Mexico could further weaken economic activity in Mexico, negatively impacting Ternium's business[134]. Supply Chain and Operational Risks - Supply chain disruptions, such as those experienced in 2023 in Argentina, negatively impacted manufacturing activity and steel demand[44]. - The company relies on a limited number of key suppliers for raw materials, with Ternium Argentina and Ternium Brasil primarily sourcing iron ore from Vale[51]. - Ternium's operations are exposed to foreign currency exchange rate fluctuations, which could adversely affect its financial results, especially since a significant portion of transactions is conducted in currencies other than the U.S. dollar[68]. - Ternium's mining activities are subject to risks including operational accidents, environmental pollution, and unexpected natural disasters, which could adversely affect profitability[88]. - Ternium's mining operations may face increased costs or delays due to changes in environmental regulations and diminished iron ore reserve grades[105]. Environmental and Regulatory Compliance - Environmental regulations and compliance costs are increasing, which may negatively impact Ternium's operations and financial condition[171]. - Ternium's steel production costs may be affected by government initiatives to reduce greenhouse gas emissions, including potential carbon taxes and cap-and-trade systems[183]. - The 2017 tax reform in Argentina introduced a tax on certain fossil fuels, expected to increase by 10% annually until 2028, potentially reaching around $10 per ton of CO2 equivalent emitted[186]. - Ternium is developing projects aimed at reducing carbon emission intensity, but these may face delays or higher-than-anticipated costs[182]. - The Corporate Sustainability Reporting Directive (CSRD) requires large listed companies to disclose information on their environmental, social, and governance impact, with amendments expected by March 19, 2027[180]. Strategic Investments and Growth - Ternium's business strategy includes significant investments and acquisitions, with a focus on expanding operations in Mexico, including a new steelmaking plant in Pesquería[52]. - Ternium's differentiation strategy includes investments in state-of-the-art technologies and expanding product research and development infrastructure[227]. - Ternium aims to strengthen its competitive position in Mexico to replace imports and better serve customers with a broader product portfolio[228]. - Ternium's strategy focuses on sophisticated value-added products and strategic growth opportunities to enhance stakeholder value[224]. - Ternium's acquisition of a participation in Usiminas in 2012 is still facing a longstanding conflict regarding certain regulatory requirements, which may lead to significant costs or deprive the company of expected synergies[55]. Financial Performance and Reporting - As of December 31, 2025, Ternium reported goodwill of $662 million related to its Mexican subsidiaries and $563 million in investments in non-consolidated companies, which are subject to impairment testing[59]. - In Q4 2025, Ternium recognized a $19 million impairment charge related to certain mining and fixed assets, and a $405 million write-down of Usiminas' deferred tax assets[60][61]. - Ternium Argentina's cash and cash equivalents amounted to $803 million as of December 31, 2025, primarily consisting of U.S. dollar-denominated sovereign bonds[145]. - Ternium is subject to complex tax regulations across multiple jurisdictions, which could adversely affect financial results due to potential double taxation and lengthy dispute resolutions[110]. - Ternium Argentina has faced restrictions on dividend payments due to local regulations, resorting to paying dividends in kind since 2022[116]. Community and Stakeholder Engagement - Ternium emphasizes health and safety, investing significantly in safety projects and training for employees and suppliers[197]. - Ternium has funded and manages two technical schools, providing advanced technical education and community programs focused on education[199]. - The company actively engages with stakeholders, including employees, customers, and local communities, to address concerns and share updates[206]. - Local community relations are critical, as disputes could lead to blockades or legal actions that disrupt mining activities[106]. - Ternium's operations in Mexico are vulnerable to water shortages and increased costs due to severe drought measures implemented by local governments[84].

Revenue Performance - Fourth quarter revenue increased 6% to $2.505 billion, exceeding guidance of low single-digit growth[9] - Full year revenue rose 3% to $8.950 billion, in line with guidance of low single-digit growth[15] - Tommy Hilfiger revenue increased 4% compared to the prior year period, while Calvin Klein revenue increased 3%[19] - Direct-to-consumer revenue increased 1%, with owned and operated store revenue flat and digital commerce revenue up 4%[19] - Total revenue for the quarter ended February 1, 2026, was $2,505.1 million, representing a 5.6% increase compared to $2,371.6 million for the same quarter last year[65] - For the year ended February 1, 2026, total revenue reached $8,950.2 million, an increase of 3.4% from $8,652.9 million in the previous year[58] - EMEA region revenue increased by 8.2% to $1,183.5 million, while the Americas saw a 4.3% increase to $764.7 million[65] - APAC region revenue remained relatively flat with a slight increase of 0.3% to $436.7 million[65] Earnings and Margins - Fourth quarter operating margin was 10.0% on a non-GAAP basis, exceeding guidance of approximately 9%[5] - Full year operating margin was 8.8% on a non-GAAP basis, exceeding guidance of approximately 8.5%[5] - Fourth quarter EPS on a non-GAAP basis was $3.82, exceeding guidance of $3.20 to $3.35[9] - Full year EPS on a non-GAAP basis was $11.40, exceeding guidance of $10.85 to $11.00[15] - 2026 EPS is projected to be in the range of $11.80 to $12.10 on a non-GAAP basis, compared to $11.40 in 2025[29] - First quarter 2026 EPS is projected to be in the range of $1.65 to $1.80 on a non-GAAP basis, compared to $(0.88) in the first quarter of 2025[35] - Earnings before interest and taxes (EBIT) on a non-GAAP basis for the quarter was $249.5 million, up from $244.4 million in the same quarter last year[52] Costs and Expenses - Gross margin decreased to 57.5% from 59.4% in the prior year, impacted by increased tariffs and promotional environment[19] - Selling, general and administrative expenses for the quarter were $1,218.3 million, compared to $1,156.7 million in the prior year, indicating a 5.3% increase[47] - Total SG&A expenses for the quarter were $1,218.3 million, an increase from $1,156.7 million in the prior year[53] - Non-GAAP SG&A expenses were $1,204.9 million for the quarter, compared to $1,150.7 million in the same quarter last year[53] - Depreciation and amortization expense for the quarter was $66.5 million, with non-GAAP depreciation and amortization expense at $64.5 million[54] Shareholder Returns - Completed over $560 million in stock repurchases during 2025, with plans for at least $300 million in 2026[5] - The company expects to repurchase at least $300 million of shares in 2026, having repurchased 7.7 million shares for $561 million in 2025[22][23] Future Outlook - Projected 2026 revenue to increase slightly compared to 2025, with operating margins stable at approximately 8.8% on a non-GAAP basis[5] - Expected DTC growth for both brands across all regions in 2026[5] - Anticipated net negative impact of approximately 215 basis points from tariffs on operating margins in 2026[5] - The 2026 outlook includes an estimated net negative impact of approximately $195 million related to tariffs, affecting EBIT by about $3.30 per share[24] - Future outlook includes potential risks from economic conditions, trade regulations, and supply chain disruptions, which could affect revenue and profitability[47] Impairments and Losses - The company incurred goodwill and other intangible asset impairments of $479.5 million for the year ended February 1, 2026[47] - The company reported a net loss of $158.3 million for the quarter, compared to a net income of $157.2 million in the same quarter last year[47] - Diluted net loss per common share was $(3.46) for the quarter, compared to $2.83 in the prior year[47] - The company reported a GAAP net loss of $44.8 million for the first quarter of 2025, which adjusted to a non-GAAP net income of $118.6 million after accounting for restructuring costs and impairment charges[67] Debt and Financial Position - The company has significant levels of outstanding debt and uses a substantial portion of its cash flows to service this debt, which may impact operational funding[47] - The company’s total assets increased to $11,681.0 million from $11,033.2 million year-over-year, marking a growth of approximately 5.9%[56] - The total stockholders' equity decreased to $4,792.3 million from $5,140.5 million, indicating a decline of about 6.8%[56] - Corporate and other expenses for the year ended February 1, 2026, amounted to $(859.3) million, slightly higher than $(852.5) million in the previous year[61] Currency Impact - Constant currency revenue information indicates a positive impact of 0.1% for the quarter and 0.5% for the year, highlighting the effects of foreign exchange rates on reported revenues[65][66] - The company emphasizes that constant currency performance should be viewed in addition to GAAP results, providing a clearer picture of underlying business trends[64]

Financial Performance - Sales increased by $664,205, or 40.8%, to $2,293,313 in 2025 from $1,629,108 in 2024, primarily due to sales of FemBloc[7] - Research and development expenses decreased by $638,839, or 7.8%, to $7,577,704 in 2025 compared to $8,216,543 in 2024[7] - Net loss was $18,627,887, or ($0.47) per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $18,816,628, or ($0.85) per share for 2024[7] - Cash and cash equivalents as of December 31, 2025, was approximately $9.3 million, with an accumulated deficit of approximately $145.8 million[7] Clinical and Regulatory Developments - Initiated patient enrollment in the FINALE pivotal clinical trial for FemBloc, a key step toward U.S. FDA approval[4] - FemBloc achieved certification under the Medical Device Single Audit Program (MDSAP), supporting global regulatory readiness[4] - FemBloc received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025[14] Strategic Partnerships - Completed $12 million financing, strengthening the balance sheet to support ongoing clinical and commercial execution[4] - Entered a strategic distribution partnership with OR Consulting to support the commercial launch of FemBloc and FemaSeed in Switzerland[4] - Established partnership with Refuah Health Center to advance adoption of FemaSeed as a first-line infertility treatment[4]

Financial Performance - Total bookings for Q4 2025 reached $19.8 million, up from $14.3 million in Q4 2024, representing a growth of 38.6%[6] - Total revenue for Q4 2025 was $87.2 million, slightly down from $88.1 million in Q4 2024, with recurring revenue constituting 94% of total revenue[6] - Financial Health revenue for Q4 2025 was $56.2 million, compared to $55.0 million in Q4 2024, accounting for 65% of total revenue[6] - GAAP net loss for Q4 2025 was $5.5 million, compared to a net loss of $5.1 million in Q4 2024[6] - Non-GAAP net income for Q4 2025 was $11.4 million, a significant increase from $1.1 million in Q4 2024[6] - Adjusted EBITDA for Q4 2025 was $19.2 million, compared to $17.9 million in Q4 2024, reflecting a growth of 7.2%[6] - For the full year 2025, total revenue was $346.8 million, up from $342.2 million in 2024, with recurring revenue also at 94%[6] - Financial Health revenue for the full year 2025 was $221.7 million, compared to $217.4 million in 2024, representing 64% of total revenue[6] - GAAP net income for the full year 2025 was $4.4 million, a turnaround from a net loss of $20.9 million in 2024[6] - Non-GAAP net income for the full year 2025 was $38.5 million, compared to $4.6 million in 2024, indicating substantial improvement in profitability[6] Assets and Liabilities - Total assets increased to $402,528, up from $395,824, representing a growth of 0.18% year-over-year[19] - Total current liabilities rose to $57,959, compared to $56,000 in the previous year, showing a slight increase of 3.5%[19] - Cash and cash equivalents at the end of the period increased to $24,850, up from $12,324, marking a growth of 102.5%[22] - The company reported a provision for credit losses of $3,002 for the year, down from $3,669 in 2024, indicating improved credit quality[22] Bookings and Revenue Segments - The new Annual Contract Value (ACV) methodology was introduced, with total bookings (ACV) for 2025 at $70,889[30] - Financial Health segment bookings for the three months ended December 31, 2025, were $11,735, up from $8,515 in 2024, a growth of 37.5%[24] - Patient Care segment bookings for the twelve months ended December 31, 2025, were $35,201, compared to $33,214 in 2024, reflecting a growth of 5.9%[24] - The total recurring revenues for the twelve months ended December 31, 2025, were $327,153, slightly up from $323,379 in 2024[40] - The total non-recurring revenues for the twelve months ended December 31, 2025, were $19,683, compared to $18,826 in 2024, showing growth in this segment[40] Adjusted Metrics - Adjusted EBITDA for the twelve months ended December 31, 2025, was $68,669, compared to $55,899 in 2024, reflecting a year-over-year increase of 22.9%[33] - The adjusted EBITDA margin for the twelve months ended December 31, 2025, improved to 19.8%, compared to 16.3% in 2024[38] - Stock-based compensation for the three months ended December 31, 2025, was $3,562, an increase from $1,823 in the same period of 2024[38] Net Income and Loss - The net income (loss) for the twelve months ended December 31, 2025, was $4,354, compared to a net loss of $20,945 in 2024, indicating a significant turnaround[38] - Non-GAAP net income for the twelve months ended December 31, 2025, was $38,541, up from $4,631 in 2024, reflecting a strong operational performance[38] - The company reported a net loss margin of (6.3%) for the three months ended December 31, 2025, compared to (5.8%) in 2024[38] Financial Statement Revisions - The company made revisions to its previously issued financial statements for the years ended December 31, 2024, and December 31, 2023, to correct errors related to revenue recognition[41] - Total revenue for the twelve months ended December 31, 2024, was $342,205, a decrease of $441 compared to previously reported figures[45] - Financial Health segment revenue was $217,366, while Patient Care segment revenue was $124,839, reflecting adjustments of $(306) and $(135) respectively[45] - Total costs of revenue amounted to $168,920, with Financial Health costs at $116,738 and Patient Care costs at $52,182, showing an increase in Patient Care costs by $542[45] - The net loss for the period was $20,945, with a net loss per share of $(1.41) on both basic and diluted bases[45] - Adjusted EBITDA for the period was $55,899, reflecting a decrease of $671 from previous calculations[45] - Accounts receivable stood at $52,952, after adjustments of $(801)[45] - Deferred revenue increased to $13,678, up by $3,025 from prior figures[45] - Retained earnings decreased to $(16,577), reflecting a reduction of $(1,625)[45] - The company reported a loss before taxes of $(10,468), which included a provision for income taxes of $10,477[45] Operational Performance Evaluation - The company emphasizes the importance of non-GAAP financial measures for evaluating operational performance and trends[46]

Exhibit 99.1 TRUBRIDGE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 RESULTS MOBILE, ALA. (March 31, 2026) – TruBridge, Inc. (NASDAQ: TBRG) ("TruBridge"), a leading provider of healthcare technology solutions for rural and community hospitals, today announced financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter Financial 2025 Highlights All comparisons are to the quarter ended December 31, 2024, unless otherwise noted. Full Year 2025 Financial Highlights All comparisons ar ...

Financial Performance - Turn Therapeutics reported a net loss of $3.19 million for the year ended December 31, 2025, compared to a net loss of $1.77 million in 2024, representing an increase of 80.4%[6] - General and Administrative (G&A) expenses rose to $5.5 million in 2025, a significant increase of 266.7% from $1.5 million in 2024, primarily due to costs associated with the company's public listing[5] - Total liabilities increased to $7.48 million in 2025 from $2.23 million in 2024, indicating a rise of 235.4%[6] Research and Development - Research and Development (R&D) expenses for 2025 were $0.3 million, up from $0.2 million in 2024, indicating a 50% increase year-over-year[5] - The Phase 2 trial for GX-03 in moderate-to-severe atopic dermatitis is on track, with topline results expected in mid-2026[2] - The company expanded its intranasal vaccine pipeline to include an intranasal influenza candidate, leveraging its proprietary delivery technology[5] Capital and Funding - Cash and cash equivalents as of December 31, 2025, were $5.08 million, excluding the $7 million in gross proceeds from the Avenue Capital facility[5] - The company secured up to $25 million in growth capital from Avenue Capital to support its cash runway through the end of 2027[3] Business Development - Turn Therapeutics entered into a global supply, development, and license agreement with Medline, aiming to generate revenue in late 2026[5] - Total assets as of December 31, 2025, were $12.16 million, compared to $2.05 million in 2024, reflecting a substantial increase[6]